Company intelligence / Profile preview

Monopteros Therapeutics Inc.

Boston, Massachusetts, United Statesmonopterostx.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Monopteros Therapeutics has initiated a Phase 1/1b open-label, dose-escalation and cohort expansion study of its lead candidate MPT‑0118 as monotherapy and in combination with pembrolizumab for patients with advanced or metastatic refractory solid tumors. The company’s approach aims to reprogram immunosuppressive regulatory T cells within the tumor microenvironment to enhance response to immune checkpoint therapy. Translational nonclinical results have shown that this mechanism can convert “cold” tumors into ones responsive to immunotherapy.

Therapeutic areas: Oncology
Modalities: Small molecule inhibitor (MALT1 inhibitor)
Industry: Biotech

Drug pipeline

2 assets

MPT-0118

1 more asset in the full pipeline.

Partnerships

Medicxi (investor/backer)

Beyond the preview

Go deeper on Monopteros Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monopteros Therapeutics Inc..